Titration of β-blockers in heart failure

References

• Califf RM, O'Connor CM. β-Blocker therapy for heart failure: the evidence is in, now the work begins. (Editorial) JAMA 2000; 283(10): 1335–7
   PubMedGoogle Scholar
• HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. Heart Failure Society of America. Pharmacotherapy 2000; 20(5): 495–522
   PubMedGoogle Scholar
• Packer M, Bristow MR, Cohn JN, et al. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334(21): 1349–55
   PubMed Web of Science ®Google Scholar
• Waagstein F, Caidahl I, Wallentin I, et al. Long-term β-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989; 80(3): 551–63
   PubMed Web of Science ®Google Scholar
• Consensus recommendations for the management of chronic heart failure: on behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999; 83(2A): 1–38A
   PubMed Web of Science ®Google Scholar
• Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MER1T-HF). MERIT-HF Study Group. JAMA 2000; 283(10): 1295–302
   PubMed Web of Science ®Google Scholar
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-1I): a randomised trial. Lancet 1999; 353(9146): 9–13
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJ, Fowler MB, et al. Effect of Carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344(22): 1651–8
   PubMed Web of Science ®Google Scholar
• Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001; 38(4): 932–8
   PubMed Web of Science ®Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353(9169): 2001–7
   PubMed Web of Science ®Google Scholar
• Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94(11): 2807–16
   PubMedGoogle Scholar
• Deedwania PC, Giles TD, Ghali JK, et al. Safety and efficacy of treatment with metoprolol CR/XL in diabetic patients with heart failure. (Ahstr) Circulation 2000; 102(18 Suppl II): 779
   PubMedGoogle Scholar
• Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol 1995; 25(5): 1154–61
   PubMedGoogle Scholar
• Haber HL, Simek CL, Gimple LW, et al. Why do patients with congestive heart failure tolerate the initiation of β-blocker therapy? Circulation 1993: 88(4 Pt 1): 1610–9
   PubMedGoogle Scholar
• Gilbert EM, Anderson JL, Deitchman D, et al. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol veisus placebo. Am J Med 1990; 88(3): 223–9
   PubMed Web of Science ®Google Scholar
• Toprol-XL package insert. Wilmington, Del: AstraZencca Pharmaceuticals, April 2001
   Google Scholar
• Coreg package insert. Philadelphia: SmithKline Beecham Pharmaceuticals, March 1999
   Google Scholar
• Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisino-pril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100(23): 2312–8
   PubMed Web of Science ®Google Scholar
• Sanderson JE, Chan SK, Yip G, et al. β-Blockade in heart failure: a comparison of Carvedilol with metoprolol. J Am Gill Cardiol 1999; 34(5): 1522–8
   PubMedGoogle Scholar
• Eichhorn EJ, Bristow MR. Practical guidelines for initiation of β-adrenergic blockade in patients with chronic heart failure. (Editorial) Am J Cardiol 1997; 79(6): 794–8
   PubMedGoogle Scholar
• Randomised, placebo-controlled trial of Carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997; 349(9049): 375–80
   PubMed Web of Science ®Google Scholar
• Bright RA, Everta DE. βblockers and depression: evidence against an association. JAMA 1992; 267(13): 1783–7
   PubMedGoogle Scholar
• Dahlof C, Dimenas E, Kendall M, et al. Quality of life in cardiovascular diseases: emphasis on β-blocker treatement. Circulation 1991; 84(6 Suppl): V1108–18
   Google Scholar
• Dimsdale JE, Newton RP, Joist T. Neuropsychological side effects of β-blockers. Arch Intern Med 1989; 149(3): 514–25
   PubMedGoogle Scholar
• Jansen RW, Gurwitz JH. Controversies surrounding the use of β-blockers in older patients with cardiovascular disease. Drugs Aging 1994; 4(3): 175–83
   PubMedGoogle Scholar
• Radack K, Deck C. β-Adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151(9): 1769–76
   PubMedGoogle Scholar
• Tsuyuki RT, McAlister FA, Teo KK. β-Blockers tor congestive heart failure: What is the current consensus? Drugs Aging 2000; 16(1): 1–7
   PubMedGoogle Scholar